The pharmaceutical landscape is witnessing a revolutionary stride with the introduction of a new, fast-absorbing CBD tablet aimed at treating insomnia. This innovation emerges from a strategic collaboration between dsm-firmenich and OMG Pharma, marking a significant leap in patient-centric healthcare.
Orally dispersible tablets are set to transform the way CBD is administered, offering a swift and efficient method of drug delivery. These tablets dissolve under the tongue, bypassing the digestive system and ensuring rapid absorption into the bloodstream.
The Science Behind the Breakthrough
The collaboration leverages dsm-firmenich’s expertise in high-quality GMP CBD active pharmaceutical ingredients and advanced formulation capabilities. The focus is on enhancing bioavailability, a critical factor in ensuring the medication’s effectiveness.
OMG Pharma’s dedication to innovative cannabinoid medicine research complements dsm-firmenich’s mission to deliver solutions that address unmet patient needs. Together, they aim to introduce the world’s first regulatory-approved over-the-counter CBD medication for sleep disorders.
The Clinical Pathway
A series of clinical trials are set to commence, with a focus on sleep, anxiety, and pain. These trials are a testament to OMG Pharma’s commitment to patient-centered research and development. The insomnia trial, in particular, will be a double-blind, randomized, placebo-controlled study involving 300 patients.
The goal is to assess the efficacy of a sublingual CBD tablet in treating insomnia, with doses ranging from 75mg to the maximum allowed under current regulations.